TAK-500
Advanced Solid Tumors
Key Facts
About Thermo Fisher Scientific
Thermo Fisher Scientific's mission is to enable its customers to make the world healthier, cleaner, and safer by providing the scientific tools and services that accelerate innovation. The company has achieved a dominant market position through strategic acquisitions, organic innovation, and the creation of an unparalleled, integrated ecosystem for the scientific community. Its strategy revolves around leveraging its scale and breadth to drive operational excellence, investing in high-growth areas like bioproduction and precision medicine, and selectively advancing an internal pipeline of novel therapeutics. With a market capitalization exceeding $178 billion, Thermo Fisher is a foundational pillar of the global life sciences industry.
View full company profileTherapeutic Areas
Other Advanced Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| NT219 | Purple Biotech | Phase 1/2 |
| INDP-101 | Indaptus Therapeutics | Phase 1 |
| PM14 | PharmaMar | Phase 1/2 |
| Ecubectedin (PM54) | PharmaMar | Phase 1 |
| AP-202 | Advance Pharmaceutical | Phase 1/2 |
| BI-1808 | BioInvent International | Phase 1/2a |
| GIGA-564 | GigaGen | Phase 1 |
| Venadaparib (IDX-1197) | Idience | Phase 1a |
| VET3-TGI | KaliVir Immunotherapeutics | Phase 1 |
| IT-141 (Etoposide IVECT™) | Intezyne | Phase 1 |
| NC318 | NextCure | Phase 1/2 |
| VisAcT (18F-AraG) Imaging in Solid Tumors | CellSight Technologies | Phase 1/2 |